Physiology of thermoregulatory dysfunction and current approaches to the treatment of vasomotor symptoms

Expert Opinion on Investigational Drugs

Volumn 14, Issue 4, 2005, Pages 435-448

  Deecher, Darlene C ^a  

^a PFIZER INC   (United States)

Author keywords

Hot flushes; Nonhormonal therapies; Thermoregulatory dysfunction; Vasomotor symptoms

Indexed keywords

ALPHA TOCOPHEROL; ANGELICA SINENSIS EXTRACT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; CIMICIFUGA RACEMOSA EXTRACT; CITALOPRAM; CLONIDINE; ESTROGEN; FLUOXETINE; GABAPENTIN; GESTAGEN; GINSENG EXTRACT; GLYCYRRHIZA EXTRACT; ISOFLAVONE; MIRTAZAPINE; NORADRENALIN; PAROXETINE; PLACEBO; PRIMROSE OIL; SEDATIVE AGENT; SEROTONIN; SERTRALINE; STEROID; TAMOXIFEN; VENLAFAXINE;

ACUPUNCTURE; BODY WEIGHT; BREAST CANCER; CIRCADIAN RHYTHM; CLINICAL TRIAL; CORE TEMPERATURE; DISEASE ASSOCIATION; DISEASE SEVERITY; ENVIRONMENTAL TEMPERATURE; EXERCISE; FEMALE; FOOD INTAKE; HORMONAL THERAPY; HOT FLUSH; HUMAN; LIFESTYLE; MAGNET; MEDICAL DECISION MAKING; MENOPAUSE; META ANALYSIS; MONKEY; NEUROCHEMISTRY; NEUROENDOCRINE SYSTEM; NEUROMODULATION; NIGHT SWEAT; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL CIRCULATION; RAT; RELAXATION TRAINING; REVIEW; SYMPTOM; SYSTEMATIC REVIEW; THERMOREGULATION; VASOMOTOR DISORDER;

ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIHYPERTENSIVE AGENTS; BODY TEMPERATURE; BODY TEMPERATURE REGULATION; CENTRAL NERVOUS SYSTEM; CLINICAL TRIALS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HOMEOSTASIS; HOT FLASHES; HUMANS; MENOPAUSE; SKIN; VASODILATION; VASOMOTOR SYSTEM;

EID: 19044375014     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.4.435     Document Type: Review

References (85)

1. THE NORTH AMERICAN MENOPAUSE SOCIETY. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause (2004) 11(1)2:11-33.
2. KRONENBERG F: Hot flashes. In: Treatment of the Postmenopausal Woman. Lobo RA (Ed.) Second Edition. Lippincott Williams & Wilkins, Philadelphia, PA, USA (1999) 2:157-177.
3. KRONENBERG F: Hot flashes: epidemiology and physiology. Ann. NY. Acad. Sci. (1990) 592:52-86.
4. McKINLAY SM, JEFFERYS M: The menopausal syndrome. Br. J. Prev. Soc. Med. (1974) 28:108-115.
5. RODSTROM K, BENGTSSON C, LISSNER L et al.: A longitudinal study of the treatment of hot flushes: the population study of women in Gothenburg during a quarter of a century. Menopause (2002) 9(3)2:156-161.
6. MOLD JW, ROBERTS M, ABOSHADY HM: Prevalence and predictors of night sweats, day sweats, and hot flashes in older primary care patients: an OKPRN study. Ann. Fam. Med. (2004) 2(5)2:391-397.
7. HUNTER MS, GRUNFELD FA, MITTAL S et al.: Menopausal symptoms in women with breast cancer: prevalence and treatment preferences. Psychooncology (2004) 13(11)2:769-778.
8. SPETZ AC, ZETTERLUND EL, VARENHORST E, HAMMAR M: Incidence and management of hot flashes in prostate cancer. J. Supp. Oncol (2003) 1(4)2:263-273.
9. MOYAD MA: Complementary/alternative therapies for reducing hot flashes in prostate cancer patients: reevaluating the existing indirect data from studies of breast cancer and postmenopausal women. Urology (2002) 59(2 Suppl. 1):20-33.
10. WORLD HEALTH ORGANIZATION: Research on the Menopause in the 1990s: Report of a WHO Scientific Group. WHO, Geneva, Switzerland: WHO Technical Report Series 866 (1996).
11. OBERMEYER CM, REYNOLDS RF, PRICE K, ABRAHAM A: Therapeutic decisions for menopause: results of the DAMES project in central Massachusetts. Menopause (2004) 11(4)2:456-465.
12. RABIN DS, CIPARRONE N, LINN ES, MOEN M: Why menopausal women do not want to take hormone replacement therapy. Menopause (1999) 6:61-67.
13. ERLIK Y, MELDRUM DR, JUDD HL: Estrogen levels in postmenopausal women with hot flashes. Obstet. Gynecol. (1982) 59(4)2:403-407.
14. THE WRITING GROUP FOR THE PEPI TRIAL: Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA (1996) 275(5):370-375.
15. BURT AM: Autonomic nervous system and hypothalamus. In: Textbook of Neuroanatomy. WB. Saunders Company, Harcourt Brace Jovanovich, Inc., Philadelphia, PA, USA (1993):392-394.
16. SIMON E, PIERAU FK, TAYLOR DC: Central and peripheral thermal control of effectors in homeothermic temperature regulation. Physiol. Rev. (1986) 66:235-300.
17. SATINOFF E: Neural organization and evolution of thermal regulation in mammals. Science (1978) 201:16-22.
18. CHARKOUDIAN N: Skin blood flow in adult human thermoregulation: how it works, when it does not, and why. Mayo Clin. Proc. (2003) 78(5):603-612.
19. ZEISBERGER E: The role of monoaminergic neurotransmitters in thermoregulation. Can. J. Physiol. Pharmacol. (1987) 65:1395-1401.
20. CHAMBERS WW, SEIGEL MS: Thermoregulatory responses of decerebrate and spinal cats. Exp. Neurol. (1974) 42:282-299.
21. LIU JC: Tonic inhibition of thermoregulation in the decerebrate monkey (Saimiri sciureus). Exp. Neurol. (1979)64:632-648.
22. SATO H: Midbrain neurons of rats responsive to hypothalamic temperature and their local thermosensitivity. J. Therm. Biol. (1984) 9:39-45.
23. FREEDMAN RR: Physiology of hot flushes. Am. J. Human Biol. (2001) 13(4):453-464.
24. JELINEK J, KAPPEN A, SCHONBAUM E, LOMAX P: A primate model of human postmenopausal hot flushes. J. Clin. Endocrinol. Metab. (1984) 59(6 Suppl. 2):1224-1228.
25. BERENDSEN HHG, WEEKS AHJ, KLOOSTERBOER HJ: Effect of tibolone and raloxifene on the tail temperature of oestrogen-deficient rats. Eur. J. Pharmacol. (2001) 419:47-54.
26. SIMPKINS JW, KATOVICH MJ, SONG IC: Similarities between morphine withdrawal in the rat and the menopausal hot flush. Life Sci. (1983) 32:1957-1966.
27. SIPE K, LEVENTHAL L, BURROUGHS K, COSMI S, JOHNSTON GH, DEECHER DC: Serotonin 2A receptors modulate tail-skin temperature in two rodent models of estrogen deficiency-related thermoregulatory dysfunction. Brain Res. (2004) 1028:191-202.
28. MERCHENTHALER I, FUNKHOUSER JM, CARVER JM, LUNDEEN SG, GHOSH K, WINNEKER RC: The effect of estrogens and antiestrogens in a rat model for hot flush. Maturitas (1998) 30:307-316.
29. LEVENTHAL L, COSMI S, DEECHER DC: Effect of calcium channel modulators on temperature regulation in ovariectomized rats. Pharmacol. Biochem. Behav. (2005) (In Press).
30. FREEDMAN RR, KRELL W. Reduced thermoregulatory null zone in postmenopausal women with hot flashes. Am. J. Obstet. Gynecol. (1999) 181(1):66-70.
31. FREEDMAN RR, NORTON D, WOODWARD S, CORNELISSEN G: Core body temperature and circadian rhythm of hot flashes in menopausal wome J. Clin. Endocrinol Metab. (1995) 80(8):2354-2358.
32. CLAR HE: Disturbances of the hypothalamic thermoregulation. Acta. Neurochir. (Wien) (1985) 75(1-4):106-112.
33. KATOVICH MJ, SIMPKINS JW, BARNEY CC: α-Adrenergic mediation of the tail skin temperature response to naloxone in morphine-dependent rats. Brain Res. (1987) 426(1):55-61.
34. MOGILNICKA E, KLIMEK V, NOWAK G, CZYRAK A: Clonidine and a beta-agonist induce hyperthermia in rats at high ambient temperature. J. Neural. Transm. (1985) 61(1-2):43-53.
35. LIN MT, CHEN FF, CHERN YF, FUNG TC: The role of the cholinergic system in the central control of thermoregulation in rats. Can. J. Physiol. Pharmacol. (1979) 57(11):1205-1212.
36. SAXENA AK, TANGRI KK, MISHRA N, VRAT S et al.: Presence of cholinoceptors in mesencephalic raphe nuclei concerned in thermoregulation in rabbits. Clin. Exp. Pharmacol. Physiol. (1984) 11(2):105-110.
37. KLANGKALYA B, CHAN A: The effects of ovarian hormones on beta-adrenergic and muscarinic receptors in rat heart. Life Sci. (1988) 42(23):2307-2314.
38. McEWEN BS, ALVES SE, BULLOCH K, WEILAND NG: Ovarian steroids and the brain: implications for cognition and aging. Neurology (1997) 48(5 Suppl. 7):S8-S15.
39. SMITH YR, MINOSHIMA S, KUHL DE, ZUBIETA JK: Effects of long-term hormone therapy on cholinergic synaptic concentrations in healthy postmenopausal women. J. Clin. Endocrinol. Metab. (2001) 86(2):679-684.
40. PANEK DU, DIXON WR: Effect of continuous intraventricular estrogen or catechol estrogen treatment on catecholamine turnover in various brain regions. J. Pharmacol. Exp. Ther. (1986) 236(3):646-652.
41. McEWEN B: Estrogen actions throughout the brain. Recent Prog. Horm. Res. (2002) 57:357-384.
42. ABDELMAWLA AH, LANGLEY RW, SZABADI E, BRADSHAW CM: Comparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline- and methoxamine-evoked constriction of the dorsal hand vein. Br. J. Clin. Pharmacol. (1999) 48(3):345-354.
43. LOPRINZI CL, KUGLER JW, SLOAN JA et al.: Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized controlled trial. Lancet (2000) 356(9247):2059-2063.
44. STEARNS V, BEEBE KL, IYENGAR M, DUBE E: Paroxetine controlled release in the treatment of menopausal hot flashes. JAMA (2003) 289(21):2827-2834.
45. REYNOLDS SR, FOSTER FI: Peripheral vascular action of estrogen observed in the ear of the rabbit. J. Pharmacol. Exp. Ther. (1940) 68:173-177.
46. GISCLARD V, FLAVAHAN NA, VANHOUTTE PM: α-Adrenergic responses of blood vessels of rabbits after ovariectomy and administration of 17 β-estradiol. J. Pharmacol. Exp. Ther. (1987) 240(2):466-470.
47. GISCLARD V, MILLER VM, VANHOUTTE PM: Effect of 17β-estradiol on endothelium-dependent responses in the rabbit. J. Pharmacol. Exp. Ther. (1988) 244(1):19-22.
48. UELAND K, PARER JT. Effects of estrogens on the cardiovascular system of the ewe. Am. J. Obstet. Gynecol. (1966) 96(3):400-406.
49. BAERUG U, WINGE T, NORLAND G, FABER-SWENSSON E: Do combinations of 1 mg estradiol and low doses of NETA effectively control menopausal symptoms? Climacteric (1998) 1(3):219-228.
50. SHULMUN LF, YANKOV V, UHL K: Safety and efficacy of a continuous once-a-week 17β-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized controlled trials. Menopause (2002) 9(3)2:195-207.
51. NIKANDER E, KIKKINEN A, METSA-HEIKKILA M et al.: A randomized placebo-controlled crossover trial with phytoestrogens in treatment of menopause in breast cancer patients. Obstet. Gynecol. (2003) 101:1213-1220.
52. TICE JA, ETTINGER B, ENSRUD K, WALLACE R et al.: Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial. JAMA (2003) 290:207-214.
53. VAN VE WEIJER PHM, BARENTSEN R: Isoflavones from red clover (Promensil) significantly reduce menopausal hot flush symptoms compared with placebo. Maturitas (2002) 42:187-193.
54. WUTTKE W, SEIDLOVA-WUTTKE D, GORKOW C: The Cimicifuga preparation BNS 1055 versus conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers. Maturitas (2003) 44(Suppl. 1):S67-S77.
55. JACOBSON JS, TROXEL AB, EVANS J et al.: Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J. Clin. Oncol. (2001) 19:2739-2745.
56. BLATT MHG, WIESBADER H, KUPPERMAN HS: Vitamin E and climacteric syndrome. Arch. Intern. Med. (1953) 91:792-796.
57. BARTON DL, LOPRINZI CL, QUELLA SK et al.: Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J. Clin. Oncol. (1998) 16:495-500.
58. BARTON DL, LOPRINZI CL, NOVOTNY P et al.: Pilot evaluation of citalopram for the relief of hot flashes. J. Support Oncol. (2003) 1:47-51.
59. SOARES CN, POITRAS JR, PROUTY J et al.: Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms. J. Clin. Psychiatry (2003) 64:473-479.
60. SUVANTO-LUUKKONEN E, KOIVUNEN R, SUNDSTRÖM H et al.: Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-bline study. Menopause (2005) 12(1):18-26.
61. LOPRINZI CL, SLOAN JA, PEREZ FA et al.: Phase III evaluation of fluoxetine for treatment of hot flashes. J. Clin. Oncol. (2002) 20(6):1578-1583.
62. STEARNS V, ISAACS C, ROWLAND J et al.: A pilot trial assessing the efficacy of paroxerine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann. Oncol. (2000) 11(1):17-22.
63. WEITZNER MA, MONCELLO J, JACOBSEN PB, MINTON S: A pilot trial of paroxetine for the treatment of hot flushes and associated symptoms in women with breast cancer. J. Pain Symptom Manage. (2002)23(4):337-345.
64. LOPRINZI CL, BARTON DL, CARPENTER LA et al.: Pilot evaluation of paroxetine for treating hot flashes in men. Mayo Clin. Proc. (2004) 79(10):1247-1251.
65. TROTT EA, LARGOZA M, HANSEN KA: An open trial of sertraline for menopausal hot flushes: potential involvement of serotonin vasomotor instability. Del. Med. J. (1997) 69(9):481-482.
66. LOPRINZI CL, KUGLER JW, SLOAN JA et al.: Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized controlled trial. Lancet (2000) 356(9247):2059-2063.
67. BARTON D, LA VB, LOPRINZI C, NOVOTNY P, WILWERDING MB, SLOAN J: Venlafaxine for the control of hot flashes: results of a longitudinal continuation study. Oncol. Nurs. Forum (2002) 29(1):33-40.
68. LOPRINZI CL, PISANSKY TM, FONSECA R et al.: Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J. Clin. Oncol. (1998) 16(7):2377-2381.
69. KALOGEROPOULOS S, KAMPAS N, PETROGIANNOPOULOS C et al.: Longterm management of menopausal hot flushes with venlafaxine. The 11th World Congress of Gynecological Endocrinology (2004) OP95:252 (Abstract).
70. QUELLA SK, LOPRINZI CL, SLOAN J et al.: Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J. Urol. (1999) 162(1):98-102.
71. PEREZ DG, LOPRINZI CL, BARTON DL et al.: Pilot evaluation of mirtazapine for the treatment of hot flashes. J. Support Oncol. (2004) 2:50-56.
72. WALDINGER MD, BERENDSEN HHG, SCHWEITZER DH: Treatment of hot flushes with mirtazapine: four case reports. Maturitas (2000) 36:165-168.
73. GUTTOSO T JR, JURLAN R, McDERMOTT MP, KIEBURTZ K: Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet. Gynecol. (2003) 101:337-345.
74. LOPRINZI CL, BARTON DL, SLOAN JA et al.: Pilot evaluation of gabapentin for treating hot flashes. Mayo Clin. Proc. (2002) 77:1159-1163.
75. ALBERTAZZI P, BOTTAZZI M, PURDIE DW: Gabapentin for the management of hot flushes: a case series. Menopause (2003) 10(3):214-217.
76. JEFFERY SM, PEPE JJ, POPOVICH LM, VITAGLIANO G: Gabapentin for hot flashes in prostate cancer. Ann. Pharmacother. (2002) 36(3)2:433-436.
77. PANDYA KJ, RAUBERTAS RF, FLYNN PJ et al.: Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann. Intern. Med. (2000) 132:788-793.
78. GOLDBERG RM, LOPRINZI CL, O'FALLON JR et al.: Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J. Clin. Oncol. (1994) 12:155-158.
79. EDINGTON RF, CHAGNON JP, STEINBERG WM: Clonidine (Dixarit) for menopausal flushing. Can. Med. Assoc. J. (1980) 123:23-26.
80. WRITING GROUP FOR THE WOMEN'S HEALTH INITIATIVE INVESTIGATORS: Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA (2002) 288(3):321-333.
81. WASSERTHEIL-SMOLLER S, HENDRIX SL, LIMACHER M: Effect of estrogen plus progestin on stroke in postmenopausal women. The Women's Health Initiative: a randomized trial. JAMA (2003) 289(20):2673-2684.
82. CHLEBOWSKI RT, HENDRIX SL, LANGER RD, STEFANIK ML: Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. The Women's Health Initiative randomized trial. JAMA (2003) 289(24):3243-3253.
83. AMERICAN CANCER SOCIETY SURVEILLANCE RESEARCH: American Cancer Society Cancer Facts & Figures 2004. National Cancer Society, Inc. (2004):1-60.
84. HERSH AL, STEFANICK ML, STAFFORD RS: National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA (2004) 291(1):47-53.
85. WRITING GROUP FOR THE WOMEN'S HEALTH INITIATIVE INVESTIGATORS: Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA (2002) 288(3):321-333.